STAT April 19, 2023
Lev Facher

The Food and Drug Administration’s latest plan to study whether opioids are effective as a chronic pain treatment is facing significant resistance from addiction and pain care experts.

A planned clinical trial, doctors and researchers argued on Wednesday, would not yield significant new information about whether opioids are effective as long-term treatments for chronic pain. The study, some charged, would be biased in favor of opioids’ efficacy — and by extension, biased in favor of painkiller manufacturers.

The pushback came during a Wednesday meeting of a federal scientific advisory committee focused on pain drugs. Throughout the hearing, members of the panel and outside experts lambasted what they viewed as inaction from the FDA, as well as perceived flaws in the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
The telehealth background of Trump's FDA pick: 6 notes
President-elect Trump's picks for CDC, FDA, surgeon general: 31 notes
Opinion: RFK Jr. and MAHA should champion a Marshall Plan for obesity
Trump picks Johns Hopkins surgeon to head FDA: 10 things to know
Regulatory Hurdles and Ethical Concerns Beset FDA Oversight of AI/ML Devices

Share This Article